Healthcare provider profile · identity verified

Bret Valentine, MD

Family Practice · MILWAUKEE, WI · NPI 1659536969

Profile state: partd only Open Payments: 2025 Medicare Part D: 2024 Last identity check: 2026-08-10 Page data build: 2026-08-12

Verified facts

What the public records show

We did not find matching Open Payments records for this doctor in 2025.

These records do not establish that a payment influenced prescribing or medical care.

Payment overview · 2025

General Payments

We did not find matching Open Payments records for this doctor in the selected program year.

Separate record types

Research & Ownership

Research Payments (direct recipient): not present in the loaded data

Associated Research Funding (for example, named PI): not present in the loaded data

Ownership / Investment: not present in the loaded data

These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.

Analysis 1 · Payment-linked products

Products named in Open Payments records

No payment-linked product analysis is available because no matching General Payment records were found for the selected year.

Public prescribing for products named in payments

There is no explicit payment-product set available for a Part D comparison.

The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.

Analysis 2 · Same-company prescribing overlap

Drugs reported in other payments from the same company that also appear in Medicare Part D

This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.

There is no payer-company set available for this comparison.

These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.

Public Medicare Part D data

Provider-and-drug rows loaded for 2024

Brand	Generic	Claims	Beneficiaries
Atorvastatin Calcium	Atorvastatin Calcium	226	61
Gabapentin	Gabapentin	124	29
Albuterol Sulfate Hfa	Albuterol Sulfate	109	35
Lisinopril	Lisinopril	97	23
Amlodipine Besylate	Amlodipine Besylate	91	25
Omeprazole	Omeprazole	76	28
Pantoprazole Sodium	Pantoprazole Sodium	75	18
Pregabalin	Pregabalin	72	11
Losartan Potassium	Losartan Potassium	71	23
Eliquis	Apixaban	70	12
Ozempic	Semaglutide	69	13
Metformin Hcl	Metformin Hcl	63	15
Tamsulosin Hcl	Tamsulosin Hcl	59	12
Buprenorphine-Naloxone	Buprenorphine Hcl/Naloxone Hcl	57	12
Metoprolol Succinate	Metoprolol Succinate	57	15
Jardiance	Empagliflozin	53	suppressed
Naproxen	Naproxen	51	19
Tizanidine Hcl	Tizanidine Hcl	51	11
Trazodone Hcl	Trazodone Hcl	48	12
Furosemide	Furosemide	47	12
Hydrocodone-Acetaminophen	Hydrocodone/Acetaminophen	44	suppressed
Fluticasone Propionate	Fluticasone Propionate	39	18
Symbicort	Budesonide/Formoterol Fumarate	38	suppressed
Allopurinol	Allopurinol	37	suppressed
Levothyroxine Sodium	Levothyroxine Sodium	37	13
Januvia	Sitagliptin Phosphate	35	suppressed
Lantus Solostar	Insulin Glargine,hum.Rec.Anlog	35	suppressed
Spironolactone	Spironolactone	35	suppressed
Trulicity	Dulaglutide	35	suppressed
Duloxetine Hcl	Duloxetine Hcl	34	suppressed
Clonazepam	Clonazepam	32	suppressed
Tradjenta	Linagliptin	32	suppressed
Zolpidem Tartrate	Zolpidem Tartrate	32	suppressed
Prednisone	Prednisone	31	22
Rosuvastatin Calcium	Rosuvastatin Calcium	31	suppressed
Clopidogrel	Clopidogrel Bisulfate	30	suppressed
Metformin Hcl Er	Metformin Hcl	30	suppressed
Mirtazapine	Mirtazapine	28	suppressed
Oxybutynin Chloride	Oxybutynin Chloride	26	suppressed
Simvastatin	Simvastatin	25	suppressed
Tramadol Hcl	Tramadol Hcl	24	suppressed
Fluticasone-Salmeterol	Fluticasone Propion/Salmeterol	23	suppressed
Montelukast Sodium	Montelukast Sodium	23	11
Potassium Chloride	Potassium Chloride	23	suppressed
Suboxone	Buprenorphine Hcl/Naloxone Hcl	23	suppressed
Triamcinolone Acetonide	Triamcinolone Acetonide	22	11
Advair Hfa	Fluticasone Propion/Salmeterol	21	suppressed
Lisinopril-Hydrochlorothiazide	Lisinopril/Hydrochlorothiazide	21	suppressed
Carvedilol	Carvedilol	20	suppressed
Hydroxyzine Hcl	Hydroxyzine Hcl	20	suppressed
Paroxetine Hcl	Paroxetine Hcl	20	suppressed
Bupropion Xl	Bupropion Hcl	19	suppressed
Hydrochlorothiazide	Hydrochlorothiazide	18	suppressed
Ibuprofen	Ibuprofen	18	suppressed
Oxycodone Hcl	Oxycodone Hcl	18	suppressed
Propranolol Hcl	Propranolol Hcl	18	suppressed
Testosterone Cypionate	Testosterone Cypionate	18	suppressed
Chlorthalidone	Chlorthalidone	17	suppressed
Ondansetron Odt	Ondansetron	16	suppressed
Sumatriptan Succinate	Sumatriptan Succinate	16	suppressed
Meloxicam	Meloxicam	15	suppressed
Tresiba Flextouch U-100	Insulin Degludec	15	suppressed
Wixela Inhub	Fluticasone Propion/Salmeterol	15	suppressed
Baclofen	Baclofen	14	suppressed
Clonidine Hcl	Clonidine Hcl	14	suppressed
Famotidine	Famotidine	14	suppressed
Sublocade	Buprenorphine	14	suppressed
Cyclobenzaprine Hcl	Cyclobenzaprine Hcl	13	suppressed
Diclofenac Sodium	Diclofenac Sodium	13	suppressed
Finasteride	Finasteride	13	suppressed
Flecainide Acetate	Flecainide Acetate	13	suppressed
Fluoxetine Hcl	Fluoxetine Hcl	13	suppressed
Glipizide Er	Glipizide	13	suppressed
Nadolol	Nadolol	13	suppressed
Novolin R Flexpen	Insulin Regular, Human	13	suppressed
Azithromycin	Azithromycin	12	11
Sertraline Hcl	Sertraline Hcl	12	suppressed
Ventolin Hfa	Albuterol Sulfate	12	suppressed
Carisoprodol	Carisoprodol	11	suppressed
Nystop	Nystatin	11	suppressed

Timeline

Payment and prescribing data by year

Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.

Year	General Payments	Main payer	Explicit products	Company overlaps	Part D coverage
2025	—	—	—	—	—
2024	—	—	—	—	Complete

Questions to ask

Questions you could discuss with your doctor

Are there reasonable alternatives I should understand when we discuss treatment options?
How should I interpret the industry-payment records shown here in the context of my care?

These are general questions generated from reviewed templates. They are not personalized medical advice.

Sources and limitations

How to read this page

Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.

Loaded source releases

Dataset	Year	Publication	Source
CMS Open Payments — General Payments	2025	2026-06-30	Original source
Medicare Part D Prescribers by Provider and Drug	2024	2026-05-06	Original source
NPPES Data Dissemination V2	current / reference data	2026-08-10	Original source

Methodology version: 2.1

Editorial template version: 2.4

Product contract version: 2.0

Schema version: 0.7.0

Page data build: 2026-08-12T23:34:59.370714+00:00

Publication policy: eligible for indexing after public-launch controls are enabled

Full methodology · Questions & answers · Report a possible error